**January, 2006**

[CURRICULUM VITAE]{.underline}

[Name]{.underline}: Joan L. Cmarik, Ph.D.

[Phone Number]{.underline}: 301-846-5641

[Email Address]{.underline}: cmarik@ncifcrf.gov

[Education]{.underline}:

1991 Ph.D., Department of Biochemistry and Center in Molecular
Toxicology, Vanderbilt University, Nashville, Tennessee

1985 B.S., Summa cum laude, Chemistry and Biology, Murray State
University, Murray, Kentucky

[Brief Chronology of Employment]{.underline}:

2002-Date Staff Scientist, Retroviral Molecular Pathogenesis Section,
Laboratory of Cancer Prevention, National Cancer Institute, Frederick,
Maryland

2000-2002 Biomedical Scientist and Breast Cancer Research Program
Coordinator, Science Applications International Corporation, Department
of Defense Congressionally Directed Medical Research Programs, Ft.
Detrick, Frederick, Maryland

1996-1999 Biotechnology Training Program Fellow**,** Gene Regulation
Section, Basic Research Laboratory, National Cancer Institute,
Frederick, Maryland

1991-1996 Postdoctoral Research Fellow**,** Gene Regulation Section,
Basic Research Laboratory, National Cancer Institute, Frederick,
Maryland

1985-1991 Graduate Student, Department of Biochemistry, Vanderbilt
University, Nashville, Tennessee

1994 Cooperative Education Student, National Center for Toxicological
Research, Division of Chemistry, Jefferson, Arkansas

[Honors and Awards]{.underline}:

1991-1996 Intramural Research Training Award, NIH

1994 Brigid Leventhal Trainee Award, Women in Cancer Research

1985-1989 University Graduate Fellowship, Vanderbilt University

1989 L. S. Hnilica Toxicology Student Lecture, Committee Chairperson

1986-1987 Vanderbilt Biochemistry Student Association, President

1980-1985 Presidential Scholarship, Murray State University

1985 Outstanding Senior Woman, Murray State University

1985 Outstanding American Chemical Society-Approved Area in Chemistry,
Murray State University

[Societies]{.underline}:

American Association for Cancer Research

HIV and Cancer Virology Faculty, National Cancer Institute

Cancer Prevention Faculty, National Cancer Institute

Staff Scientist and Staff Clinician Organization, National Cancer
Institute

[Publications]{.underline}:

1\. Thompson, H.C., Jr., Gosnell, A.B., Holder, C.L., Siitonen, P.H.,
Rowland, K.L., and Cmarik, J.L.: Metabolism of doxylamine succinate in
Fischer 344 rats, Part I: distribution and excretion. *J.* *Analy. Tox.*
10: 18-23, 1986.

2\. Inskeep, P.B., Koga, N., Cmarik, J.L., and Guengerich, F.P.:
Covalent binding of 1,2-dihaloalkanes to DNA and stability of the major
DNA adduct, *S*-\[2-(*N*^7^-guanyl)ethyl\]glutathione. *Cancer Res.* 46:
2839-2844, 1986.

3\. Thompson, H.C., Jr., Holder, C.L., Siitonen, P.H., Rowland, K.L.,
Gosnell, A.B., and Cmarik, J.L.: Metabolism of pyrilamine maleate in
Fischer 344 rats, Part I: Activity excretion profiles. *J.* *Analy.
Tox.* 11: 252-256, 1987.

4\. Humphreys, W.G., Kim, D.-H., Cmarik, J.L., Shimada, T., and
Guengerich, F.P.: Comparison of the DNA alkylating properties and
mutagenic responses caused by a series of *S*-(2-haloethyl)-substituted
cysteine and glutathione derivatives. *Biochemistry* 29: 10342-10350,
1990.

5\. Cmarik, J.L., Inskeep, P.B., Meyer, D.J., Meredith, M.J., Ketterer,
B., and Guengerich, F.P.: Selectivity of rat and human glutathione
*S*-transferases in activation of ethylene dibromide by glutathione
conjugation and DNA binding and induction of unscheduled DNA synthesis
in human hepatocytes. *Cancer Res.* 50: 2747-2752, 1990.

6\. Bowling, J.M., Bruner, K.L., Cmarik, J.L., and Tibbetts, C.:
Neighboring nucleotide interactions during DNA sequencing gel
electrophoresis. *Nucleic Acids Res.* 19: 3089-3097, 1991.

7\. Cmarik, J.L., Humphreys, W.G., Bruner, K.L, Lloyd, R.S., Tibetts,
C., and Guengerich, F.P.: Mutation spectrum and sequence alkylation
selectivity resulting from modification of bacteriophage M13mp18 DNA
with *S*-(2-chloroethyl) glutathione: evidence for a role of
*S*-\[2-(*N*^7^-guanyl)ethyl\] glutathione as a mutagenic lesion formed
from ethylene dibromide. *J. Biol. Chem.* 267: 6672-6679, 1992.

8\. Cmarik, J.L., Herschman, H., and Colburn, N.H.: Preferential
primary-response gene expression in promotion-resistant versus
promotion-sensitive JB6 cells. *Mole. Carc.* 11: 115-124, 1994.

9\. Dong, Z., Cmarik, J.L., Wendel, E.J., and Colburn, N.H.:
Differential transformation efficiency but not AP-1 induction under
anchorage-dependent and -independent conditions. *Carcinogenesis* 15:
1001-1004, 1994.

10\. Cmarik, J.L., Li, Y., Ogram, S.A., Min, H., Reeves, R., and
Colburn, N.H.: Tumor promoter induces high mobility group HMG-Y protein
expression in transformation-sensitive but not -resistant cells.
*Oncogene* 16: 3387-3396, 1998.

11\. Cmarik, J.L**.**, Min, H., Hegamyer, G., Zhan, S., Kulesz-Martin,
M., Yoshinaga, H., Matsuhashi, S., and Colburn, N.H.: Differentially
expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic
transformation. *Proc. Natl. Acad. Scis. USA* 96: 14037-14042, 1999.

12 Cmarik, J.L., Hegamyer, G., Gerrard, B., Dean, M., and Colburn, N.H.:
cDNA cloning and mapping of mouse pleckstrin (Plek), a gene upregulated
in transformation-resistant cells. *Genomics* 66: 204-212, 2000.

13\. Yang, H.S., Jansen, A.P., Nair, R., Shibahara, K., Verma, A.K.,
Cmarik, J.L., and Colburn, N.H.: A novel transformation suppressor,
Pdcd4, inhibits AP-1 transactivation but not NF-B or ODC
transactivation. *Oncogene* 20: 669-676, 2001.

14\. Nishigaki, K., Thompson, D., Yugawa, T., Rulli, K., Hanson, C.,
Cmarik, J., Gutkind, J.S., Teramoto, H., and Ruscetti, S.:
Identification and characterization of a novel Ste20/germinal center
kinase-related kinase, polyploidy-associated protein kinase. *J. Biol.
Chem.* 278: 13520-13530, 2003.

[Manuscripts Submitted]{.underline}:

15\. Yugawa, T., Nishigaki, K., Cmarik, J., Hanson, C., Thompson, D.,
and Ruscetti, S.: Involvement of apoptosis-related molecules in the
induction of Epo-independent proliferation of erythroid cells infected
with the Friend spleen focus-forming virus. Submitted, 2005.

[Book Chapters, Invited Submissions, and Published Proceedings of
Symposia]{.underline}:

1\. Cmarik, J.L., and Owen, D.A.: Models for highly phenylated trasition
metal-containing polymers; derivatives of the
pentaphenylcylclopentadienyl ligand. *Proc. A.C.S. Div. Polymeric
Materials Sci. and Eng.* 49: 353-357, 1983.

2\. Inskeep, P.B., Koga, N., Cmarik, J.L., Peterson, L.A., and
Guengerich, F.P.: Structural and chemical characterization of
*S*-\[2-(*N*^7^-guanyl)ethyl\]glutathione, the major DNA adduct formed
from 1,2-dibromoethane*. Fed. Proc.* 45: 1626, 1986.

3\. Guengerich, F.P., Cmarik, J.L., Peterson, L.A., Koga, N., and
Inskeep, P.B.: Glutathione-mediated formation of *vic*-dihaloalkane/DNA
adducts. *In* *Glutathione S-Transferases and Carcinogenesis* (Mantle,
T.J., Pickett, C.B., and Hayes, J.D., eds.), Taylor and Francis, London,
pp. 189-197, 1987..

4\. Guengerich, F.P., Peterson, L.A., Cmarik, J.L., Koga, N., and
Inskeep, P.B.: Activation of dihaloalkanes by glutathione conjugation
and formation of DNA adducts. *Env. Health Perspectives* 76: 15-18,
1987.

5\. Guengerich, F.P., Humphreys, W.G., Kim, D.-H., Oida, T., and Cmarik,
J.L.: DNA-glutathione adducts derived from *vic*-dihaloalkanes:
mechanisms of mutagenesis. *In* *Xenobiotics and Cancer* (Ernster, L.,
et al., eds.) Japan Scientific Society Press, Tokyo, Japan/Taylor and
Francis, Ltd., London, England, pp. 101-107, 1991.

6\. Guengerich, F.P., Min, K.-S., Persmark, M., Kim, M.-S., Humphreys,
W.G., Cmarik, J., and Thier, R.: Dihaloalkanes and polyhaloalkanes. *In*
*DNA Adducts: Identification and Biological Significance* (Hemminki,K.,
et al., eds.) International Agency for Research on Cancer, Lyon, France,
pp. 57-72, 1994.

7\. Cmarik, J.L., and Colburn, N.H.: Use of mouse JB6 cells to identify
molecular targets and novel agents for prevention of carcinogenesis.
*In* *Food Factors for Cancer Prevention* (Ohigashi, H., et al., eds.)
Springer-Verlag, Tokyo, Japan, pp. 67-76, 1997.

8\. Hsu, T.-C., Young, M., Cmarik, J.L., and Colburn, N.: Activator
Protein-1 (AP-1) and NF-B dependent transcriptional events in
carcinogenesis. *In* Signal Transduction by Oxidant Stresses, *Free
Radical Biology & Medicine* 28: 1338-1348, 2000.

9\. Dong, Z. and Cmarik, J.L.: Harvesting Cells under
Anchorage-Independent Cell Transformation Conditions for Biochemical
Analyses. *Science STKE* 2002: PL7, 2002.

[Abstracts]{.underline}:

1\. Cmarik, J.L., Inskeep, P.B., Meyer, D.J., Coles, B., Meredith, M.J.,
Ketterer, B., and Guengerich, F.P.: Activation of ethylene dibromide by
glutathione conjugation: selectivity of rat and human glutathione
*S*-transferases and DNA binding and induction of unscheduled DNA
synthesis in human hepatocytes. Gordon Research Conference on Drug
Metabolism, Plymouth, New Hampshire, 18-24 July, 1988.

2\. Cmarik, J.L., Inskeep, P.B., Meredith, M.J., Meyer, D.J., Ketterer,
B., and Guengerich, F.P.: Activation of ethylene dibromide by
glutathione conjugation in rat and human systems. Brookhaven Symposium
on DNA Damage and Repair in Human Tissues, Upton, Long Island, New York,
1-4 October, 1989.

3\. Cmarik, J.L., Lloyd, R.S., Bruner, K.L., Tibbetts, C., and
Guengerich, F.P.: Mutational spectrum resulting from DNA adducts of
1,2-dibromoethane. *Proc. Amer. Assoc. Cancer Res.* 32: 102., 1991.

4\. Cmarik, J.L. and Colburn, N.H.: Differential induction of TIS
(TPA-inducible sequence) mRNAs by TPA in transformation-responsive and
resistant JB6 cell lines. *Proc. Amer. Assoc. Cancer Res.* 34: 510,
1993.

5\. Cmarik, J.L., Herschman, H., and Colburn, N.H.: The TIS1 and TIS21
primary response genes are candidate tumor promotion suppressor genes.
*J. Cell. Biochem.,* Keystone Symposia on Molecular & Cellular Biology
Supplement 18C: 187, 1994.

6\. Cmarik, J.L., Hegamyer, G., and Colburn, N.H.: Candidate mediators
or inhibitors of neoplastic transformation identified by mRNA
differential display. *Proceedings of the American Association for
Cancer Research* 37:518, 1996.

7\. Cmarik, J.L., Li, Y., Ogram, S.A., Min, H., Reeves, R., and Colburn,
N.H.: High mobility group HMG-Y protein is induced by tumor promoter in
transformation-sensitive but not -resistant cells. *Proc. Amer. Assoc.
Cancer Res.* 39:450, 1998.

8\. Cmarik, J.L., Hegamyer, G., and Colburn, N.H.: Novel molecular
targets for cancer prevention identified by mRNA differential display.
First Ann. Mtg. on the Exp. Thera.of Human Cancer, Frederick, Maryland,
11-13 June, 1998.

9\. Cmarik, J.L., Min, H., Hegamyer, G., and Colburn, N.H.: Novel
differentially expressed protein inhibits tumor promoter-induced
neoplastic transformation. 15th Ann. Mtg. on Oncogenes and Tumor
Suppressors, Frederick, MD, 22-27 June, 1999.

10\. Rulli, K., Yugawa, T., Nishigaki, K., Hanson, C., Cmarik, J., and
Ruscetti, S.: *Ex vivo* and *in vivo* biological effects of a truncated
form of the receptor tyrosine kinase STK activated by interaction with
the SFFV envelope glycoprotein or by point mutation. 15th Intl. Workshop
on Retroviral Pathogenesis, Glasgow, Scotland, 17-21 September, 2003.

11\. Yiannoulos, G., Cmarik, J., Ruscetti, S.K., Hoffman, P.M., and
Wilt, S.G.: Minocycline delays disease onset and microglial activation
in a rat retroviral neuroinflammatory disease. Society for Neuroscience
Ann. Mtg., New Orleans, Louisiana, 8-12 November, 2003.

12\. Cmarik, J., MacPherson, G., Hanson, C., and Ruscetti, S.:
Neurological Disease Induced by Murine Leukemia Virus PVC-211. First
Annual CCR Staff Scientist and Staff Clinician Retreat, Rockville,
Maryland, 25 April, 2005.